The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence and prediction of checkpoint inhibitor immune-related nephrotoxicity.
 
Jonathan D Sorah
No Relationships to Disclose
 
Tracy L. Rose
Research Funding - Bristol-Myers Squibb; GeneCentric; Merck; Roche/Genentech; X4 Pharma
 
Roshni Radhakrishna
No Relationships to Disclose
 
Vimal Derebail
Honoraria - RTI International
Consulting or Advisory Role - Novartis; Retrophin
Research Funding - ChemoCentryx; Gilead Sciences; InflaRx; Otsuka; Pfizer; Retrophin
 
Matthew I. Milowsky
Consulting or Advisory Role - BioClin Therapeutics
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); Jounce Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst); X4 Pharma (Inst)
Other Relationship - Asieris Pharmaceuticals